Is DCOY or ERNA more profitable?

Ernexa Therapeutics' return on equity of -305.93% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -315.22% -167.15% Ernexa Therapeutics N/A -305.93% -169.86%

Do analysts prefer DCOY or CELZ?

Decoy Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 986.96%. Given Decoy Therapeutics' higher probable upside, research analysts plainly believe Decoy Therapeutics is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is DCOY or CELZ more profitable?

Creative Medical Technology's return on equity of -86.52% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -315.22% -167.15% Creative Medical Technology N/A -86.52% -81.96%

Do analysts recommend DCOY or AQB?

Decoy Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 986.96%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Decoy Therapeutics is more favorable than AquaBounty Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is DCOY or AQB more profitable?

AquaBounty Technologies' return on equity of -147.07% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -315.22% -167.15% AquaBounty Technologies N/A -147.07% -28.73%

Do analysts recommend DCOY or LABT?

Decoy Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 986.96%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Decoy Therapeutics is more favorable than Lakewood-Amedex Biotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, DCOY or LABT?

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decoy Therapeutics N/A N/A -$12.52M -$30.37 N/A Lakewood-Amedex Biotherapeutics N/A N/A -$3.85M -$4.75 N/A

Is DCOY or LABT more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -315.22% -167.15% Lakewood-Amedex Biotherapeutics N/A N/A N/A

Decoy Therapeutics (DCOY) Competitors

$2.76 -0.12 (-4.17%)

As of 09/4/2026 03:57 PM Eastern

Compare

DCOY vs. ERNA, BOLT, CELZ, AQB, and LABT

Should you buy Decoy Therapeutics stock or one of its competitors? Decoy Therapeutics's main competitors and comparable companies include Ernexa Therapeutics (ERNA), Bolt Biotherapeutics (BOLT), Creative Medical Technology (CELZ), AquaBounty Technologies (AQB), and Lakewood-Amedex Biotherapeutics (LABT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Decoy Therapeutics compare to Ernexa Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 1.5% of Decoy Therapeutics shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Decoy Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.61, indicating that its share price is 161% more volatile than the broader market.

Decoy Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 986.96%. Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 596.06%. Given Decoy Therapeutics' higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ernexa Therapeutics' return on equity of -305.93% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

In the previous week, Decoy Therapeutics' average media sentiment score of 0.00 equaled Ernexa Therapeutics'average media sentiment score.

Company	Overall Sentiment
Decoy Therapeutics	Neutral
Ernexa Therapeutics	Neutral

Decoy Therapeutics has higher earnings, but lower revenue than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A
Ernexa Therapeutics	$580K	12.11	-$14.08M	-$14.35	N/A

Summary

Decoy Therapeutics and Ernexa Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Decoy Therapeutics compare to Bolt Biotherapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Decoy Therapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Bolt Biotherapeutics' return on equity of -126.23% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%

In the previous week, Decoy Therapeutics' average media sentiment score of 0.00 equaled Bolt Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
Decoy Therapeutics	Neutral
Bolt Biotherapeutics	Neutral

Decoy Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 986.96%. Bolt Biotherapeutics has a consensus price target of $14.50, suggesting a potential upside of 271.79%. Given Decoy Therapeutics' higher possible upside, equities analysts clearly believe Decoy Therapeutics is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 1.5% of Decoy Therapeutics shares are owned by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Decoy Therapeutics has higher earnings, but lower revenue than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A
Bolt Biotherapeutics	$7.70M	0.98	-$33.38M	-$16.44	N/A

Summary

Bolt Biotherapeutics beats Decoy Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Decoy Therapeutics compare to Creative Medical Technology?

Decoy Therapeutics (NASDAQ:DCOY) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Creative Medical Technology has higher revenue and earnings than Decoy Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A
Creative Medical Technology	$10K	731.49	-$5.99M	-$2.07	N/A

Decoy Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

Decoy Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 986.96%. Given Decoy Therapeutics' higher probable upside, research analysts plainly believe Decoy Therapeutics is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Creative Medical Technology's return on equity of -86.52% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
Creative Medical Technology	N/A	-86.52%	-81.96%

In the previous week, Creative Medical Technology had 1 more articles in the media than Decoy Therapeutics. MarketBeat recorded 1 mentions for Creative Medical Technology and 0 mentions for Decoy Therapeutics. Creative Medical Technology's average media sentiment score of 1.75 beat Decoy Therapeutics' score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Decoy Therapeutics	Neutral
Creative Medical Technology	Very Positive

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 1.5% of Decoy Therapeutics shares are owned by company insiders. Comparatively, 1.0% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Creative Medical Technology beats Decoy Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Decoy Therapeutics compare to AquaBounty Technologies?

Decoy Therapeutics (NASDAQ:DCOY) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Decoy Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 986.96%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Decoy Therapeutics is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 1.5% of Decoy Therapeutics shares are owned by insiders. Comparatively, 1.0% of AquaBounty Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Decoy Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, AquaBounty Technologies has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

AquaBounty Technologies' return on equity of -147.07% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
AquaBounty Technologies	N/A	-147.07%	-28.73%

In the previous week, Decoy Therapeutics' average media sentiment score of 0.00 equaled AquaBounty Technologies'average media sentiment score.

Company	Overall Sentiment
Decoy Therapeutics	Neutral
AquaBounty Technologies	Neutral

Decoy Therapeutics has higher earnings, but lower revenue than AquaBounty Technologies. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A
AquaBounty Technologies	$2.47M	2.40	-$18.49M	-$0.82	N/A

Summary

Decoy Therapeutics beats AquaBounty Technologies on 7 of the 12 factors compared between the two stocks.

How does Decoy Therapeutics compare to Lakewood-Amedex Biotherapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

11.9% of Decoy Therapeutics shares are held by institutional investors. 1.5% of Decoy Therapeutics shares are held by insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Decoy Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 986.96%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Decoy Therapeutics is more favorable than Lakewood-Amedex Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lakewood-Amedex Biotherapeutics had 4 more articles in the media than Decoy Therapeutics. MarketBeat recorded 4 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Decoy Therapeutics. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.78 beat Decoy Therapeutics' score of 0.00 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Decoy Therapeutics	Neutral
Lakewood-Amedex Biotherapeutics	Positive

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	-$3.85M	-$4.75	N/A

Summary

Lakewood-Amedex Biotherapeutics beats Decoy Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Decoy Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCOY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCOY vs. The Competition

Export

Metric	Decoy Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.76M	$4.01B	$7.25B	$12.92B
Dividend Yield	N/A	3.60%	2.53%	9.14%
P/E Ratio	-0.09	12.71	273.54	25.43
Price / Sales	N/A	1,346.87	625.17	94.95
Price / Cash	N/A	108.60	77.08	52.44
Price / Book	0.42	16.14	12.85	6.17
Net Income	-$12.52M	-$22.80M	$3.49B	$350.08M
7 Day Performance	-4.83%	0.31%	1.04%	-0.14%
1 Month Performance	-34.13%	8.25%	5.52%	1.02%
1 Year Performance	N/A	49.17%	24.39%	14.51%

Decoy Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCOY Decoy Therapeutics	2.4542 of 5 stars	$2.76 -4.2%	$30.00 +987.0%	N/A	$1.76M	N/A	N/A	20
ERNA Ernexa Therapeutics	1.982 of 5 stars	$4.57 -3.6%	$30.00 +556.5%	-85.9%	$7.73M	$580K	N/A	10
BOLT Bolt Biotherapeutics	2.4779 of 5 stars	$3.82 -4.5%	$14.50 +279.6%	-19.4%	$7.71M	$7.70M	N/A	90	Positive News
CELZ Creative Medical Technology	1.3394 of 5 stars	$1.14 flat	N/A	-66.3%	$7.52M	$10K	N/A	5	Positive News
AQB AquaBounty Technologies	0.1493 of 5 stars	$1.25 -4.6%	N/A	-10.2%	$6.74M	$2.47M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCOY) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Decoy Therapeutics (DCOY) Competitors

DCOY vs. ERNA, BOLT, CELZ, AQB, and LABT

How does Decoy Therapeutics compare to Ernexa Therapeutics?

Summary

How does Decoy Therapeutics compare to Bolt Biotherapeutics?

Summary

How does Decoy Therapeutics compare to Creative Medical Technology?

Summary

How does Decoy Therapeutics compare to AquaBounty Technologies?

Summary

How does Decoy Therapeutics compare to Lakewood-Amedex Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Decoy Therapeutics (DCOY) Competitors

DCOY vs. ERNA, BOLT, CELZ, AQB, and LABT

How does Decoy Therapeutics compare to Ernexa Therapeutics?

Do insiders and institutionals hold more shares of DCOY or ERNA?

Which has more risk & volatility, DCOY or ERNA?

Do analysts prefer DCOY or ERNA?

Is DCOY or ERNA more profitable?

Does the media favor DCOY or ERNA?

Which has stronger valuation and earnings, DCOY or ERNA?

Summary

How does Decoy Therapeutics compare to Bolt Biotherapeutics?

Is DCOY or BOLT more profitable?

Does the media favor DCOY or BOLT?

Which has more volatility & risk, DCOY or BOLT?

Do analysts prefer DCOY or BOLT?

Do insiders & institutionals hold more shares of DCOY or BOLT?

Which has better valuation & earnings, DCOY or BOLT?

Summary

How does Decoy Therapeutics compare to Creative Medical Technology?

Which has stronger earnings and valuation, DCOY or CELZ?

Which has more risk and volatility, DCOY or CELZ?

Do analysts prefer DCOY or CELZ?

Is DCOY or CELZ more profitable?

Does the media prefer DCOY or CELZ?

Do institutionals and insiders believe in DCOY or CELZ?

Summary

How does Decoy Therapeutics compare to AquaBounty Technologies?

Do analysts recommend DCOY or AQB?

Do insiders and institutionals believe in DCOY or AQB?

Which has more volatility & risk, DCOY or AQB?

Is DCOY or AQB more profitable?

Does the media favor DCOY or AQB?

Which has higher earnings and valuation, DCOY or AQB?

Summary

How does Decoy Therapeutics compare to Lakewood-Amedex Biotherapeutics?

Do insiders & institutionals believe in DCOY or LABT?

Do analysts recommend DCOY or LABT?

Does the media prefer DCOY or LABT?

Is DCOY or LABT more profitable?

Which has preferable valuation and earnings, DCOY or LABT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools